Ondine Biomedical (UK) Today

OBI Stock   8.00  0.13  1.60%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Over 88

 
High
 
Low
Very High
Ondine Biomedical is trading at 8.00 as of the 28th of November 2024, a 1.6 percent decrease since the beginning of the trading day. The stock's lowest day price was 7.76. Ondine Biomedical has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Ondine Biomedical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Ondine Biomedical is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 426.23 M outstanding shares. More on Ondine Biomedical

Moving against Ondine Stock

  0.8HYUD Hyundai MotorPairCorr
  0.66RIGD Reliance IndustriesPairCorr
  0.54SMSD Samsung ElectronicsPairCorr
  0.52SMSN Samsung ElectronicsPairCorr

Ondine Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ondine Biomedical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ondine Biomedical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO FounderCFA CFA
Thematic IdeaDrugs (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Drugs, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Ondine Biomedical's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ondine Biomedical's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Ondine Biomedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ondine Biomedical's financial leverage. It provides some insight into what part of Ondine Biomedical's total assets is financed by creditors.
Liquidity
Ondine Biomedical cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Ondine Biomedical has accumulated 541 K in total debt. Debt can assist Ondine Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Ondine Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ondine Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ondine to invest in growth at high rates of return. When we think about Ondine Biomedical's use of debt, we should always consider it together with cash and equity.

Free Cash Flow

(13.14 Million)
Ondine Biomedical (OBI) is traded on London Exchange in UK and employs 14 people. Ondine Biomedical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.62 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ondine Biomedical's market, we take the total number of its shares issued and multiply it by Ondine Biomedical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ondine Biomedical operates under Biotechnology sector and is part of Health Care industry. The entity has 426.23 M outstanding shares. Ondine Biomedical generates negative cash flow from operations
Check Ondine Biomedical Probability Of Bankruptcy
Ownership Allocation
Ondine Biomedical owns a total of 426.23 Million outstanding shares. Ondine Biomedical has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ondine Ownership Details

Ondine Biomedical Risk Profiles

Although Ondine Biomedical's alpha and beta are two of the key measurements used to evaluate Ondine Biomedical's performance over the market, the standard measures of volatility play an important role as well.

Ondine Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Ondine Biomedical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now

   

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Ondine Biomedical Corporate Management

Elected by the shareholders, the Ondine Biomedical's board of directors comprises two types of representatives: Ondine Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ondine. The board's role is to monitor Ondine Biomedical's management team and ensure that shareholders' interests are well served. Ondine Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ondine Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mike LongVP OperationsProfile
Nikita ParkhaevCompany SecretaryProfile
Elaine CPACorporate ControllerProfile
Joseph ErricoChief OfficerProfile

Other Information on Investing in Ondine Stock

Ondine Biomedical financial ratios help investors to determine whether Ondine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ondine with respect to the benefits of owning Ondine Biomedical security.